For instance, pemigatinib has received approval for the management of advanced cholangiocarcinoma because of its potent activity as a selective oral small-molecule inhibitor of FGFR1, FGFR2, and FGFR3.[12]. Here, FGFR3 is linked to cholangiocarcinoma.